Tax-related share sale by Disc Medicine (IRON) Chief Legal Officer

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Legal Officer Rahul Khara reported an open-market sale of 2,853 shares of common stock at an average price of $62.86 per share on February 17, 2026. According to the filing, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units, not a discretionary sale. After this transaction, Khara directly owned 52,173 shares of Disc Medicine common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khara Rahul

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		2,853	D	$62.86	52,173	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I. This sale is a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

	By: /s/ Rahul Khara	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Disc Medicine (IRON) report for Rahul Khara?

Disc Medicine’s Chief Legal Officer, Rahul Khara, reported selling 2,853 common shares. The shares were sold at an average price of $62.86 each to cover tax withholding on vesting restricted stock units, and were not a discretionary share sale by the executive.

Why did Rahul Khara sell Disc Medicine (IRON) shares in this Form 4?

The filing states the sale was to cover tax withholding obligations tied to vesting restricted stock units. This “sell to cover” structure means the transaction was administrative for tax purposes rather than a discretionary decision to reduce his investment in Disc Medicine.

How many Disc Medicine (IRON) shares did Rahul Khara sell and at what price?

Rahul Khara sold 2,853 shares of Disc Medicine common stock. The reported average sale price was $62.86 per share. The transaction code “S” identifies it as a sale in the open market or a private transaction under the Form 4 reporting rules.

How many Disc Medicine (IRON) shares does Rahul Khara own after this transaction?

After completing the tax-related sale, Rahul Khara directly owned 52,173 Disc Medicine common shares. This post-transaction balance reflects his remaining equity stake as reported in the Form 4’s ownership column following the 2,853-share “sell to cover” transaction on February 17, 2026.

Was Rahul Khara’s Disc Medicine (IRON) share sale a discretionary trade?

No, the Form 4 footnote explains the sale was not discretionary. It was executed solely to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, a common administrative step when equity awards convert into taxable income.